Who is the CEO of Freenome?

Aaron Elliott is listed as CEO or top operating leader. The leadership block also names other public founders or executives relevant to sellers and partners.

Diagnostics

What is Freenome?

Q: What does Freenome do?

Freenome Freenome is a biotech company developing blood-based cancer screening tests using multiomics, machine learning, and clinical studies. It announced a SPAC business combination intended to create a public company and fund 2026 launches of multiple tests.. The profile reflects public information as of June 2026 and avoids private revenue, office, email, or pricing assumptions.

Q: How much has Freenome raised?

Freenome's funding view is Over $1B lifetime financing; $330M SPAC/deal expected. Freenome raised $270M Series C, $300M Series D, additional Roche-led capital including $254M in 2024, and announced a $330M SPAC/PIPE-style business combination in late 2025.

Q: Who are Freenome's competitors?

Freenome competes with Guardant Health, Exact Sciences, Grail, and other companies in diagnostics. The competitor list includes primary domains for directory logos.

AI and multiomics blood-test company developing early cancer screening products.

Category: Diagnostics
Headquarters: South San Francisco, CA
Founded: 2014
Employees: 500+ reported
Total funding: Over $1B lifetime financing; $330M SPAC/deal expected
Valuation: SPAC agreement announced; valuation not fully closed public-market status

What is Freenome?

Freenome is a biotech company developing blood-based cancer screening tests using multiomics, machine learning, and clinical studies. It announced a SPAC business combination intended to create a public company and fund 2026 launches of multiple tests.

Freenome has a scale profile that matters to sellers: 500+ reported, Over $1B lifetime financing; $330M SPAC/deal expected, and SPAC agreement announced; valuation not fully closed public-market status. Public sources give enough product and funding detail to profile the company, but private revenue, customer-level pricing, personal emails, and complete internal office lists are not invented here.

Sources:Freenome overview Freenome official site

What does Freenome offer?

Freenome offers Multiomics platform, Colorectal cancer screening, Multi-cancer detection pipeline, PREEMPT CRC study, and related services.

Multiomics platform· Science
Colorectal cancer screening· Product
Multi-cancer detection pipeline· Product
PREEMPT CRC study· Clinical
Roche ex-U.S. collaboration· Partnership
AI/ML biomarker analysis· Technology

Sources:Freenome product page Freenome overview source

How does Freenome make money?

Freenome’s future model is diagnostics commercialization: lab testing, reimbursement, health-system/channel partnerships, ex-U.S. licensing, and potential royalties; it does not publish consumer list pricing before broad commercial launch.

Growth is driven by adoption in diagnostics, expansion into larger accounts or programs, and operational execution. Where list prices are public, this profile uses them; where pricing is contract-specific, it explicitly treats pricing as custom rather than inventing unit economics.

Sources:Freenome business/pricing Freenome official site

Who leads Freenome?

Freenome is led by Aaron Elliott with public founders and executives supporting diagnostics scale.

Aaron ElliottCEONamed CEO 2025Leads commercial growth and product innovation.
Riley EnnisCo-founderSince 2014Led interim Office of CEO during transition.
C. Jimmy LinChief Scientific OfficerExecutive teamScientific leader for multiomics cancer detection.

Sources:Freenome leadership/source Freenome careers

Who are Freenome's decision-makers?

How do you contact Freenome's leadership?

Freenome does not publish verified personal executive emails in the sources used. Use public company contact, support, sales, investor, or careers paths rather than guessed personal addresses.

Email formatPublic contact/support/sales route; personal format not verified

Aaron ElliottCEOhttps://www.freenome.com
Riley EnnisCo-founderhttps://www.freenome.com
C. Jimmy LinChief Scientific Officerhttps://www.freenome.com

Sources:Freenome contact Freenome careers/contact

How much funding has Freenome raised?

Freenome raised $270M Series C, $300M Series D, additional Roche-led capital including $254M in 2024, and announced a $330M SPAC/PIPE-style business combination in late 2025.

a16z lists Freenome on its public investment list where applicable. The latest valuation/status used here is SPAC agreement announced; valuation not fully closed public-market status; for public or soon-to-be-public companies, current market status or transaction status is more useful than stale private marks.

Sources:Freenome funding Freenome funding/business a16z investment list

How much has Freenome raised?

How did Freenome get here?

Freenome reached its current scale through product expansion, major financing, and category execution.

2014FoundedFreenome is founded in South San Francisco, CA.
GrowthProduct-market expansionThe company scales its diagnostics product surface.
Major roundMajor financingFreenome raised $270M Series C, $300M Series D, additional Roche-led capital including $254M in 2024, and announced a $330M SPAC/PIPE-style business combination in late 2025.
2025Current scale signalPublic sources show 500+ reported and SPAC agreement announced; valuation not fully closed public-market status.
June 2026Directory snapshotProfile refreshed as of June 2026.